GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CervoMed Inc (NAS:CRVO) » Definitions » Cyclically Adjusted Price-to-FCF

CRVO (CervoMed) Cyclically Adjusted Price-to-FCF : (As of Jun. 03, 2025)


View and export this data going back to 1996. Start your Free Trial

What is CervoMed Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


CervoMed Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for CervoMed's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CervoMed Cyclically Adjusted Price-to-FCF Chart

CervoMed Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CervoMed Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CervoMed's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, CervoMed's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CervoMed's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CervoMed's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where CervoMed's Cyclically Adjusted Price-to-FCF falls into.


;
;

CervoMed Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

CervoMed's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, CervoMed's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.447/134.9266*134.9266
=-0.447

Current CPI (Mar. 2025) = 134.9266.

CervoMed Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -504.000 100.684 -675.411
201509 -492.500 100.392 -661.922
201512 -764.333 99.792 -1,033.434
201603 -514.667 100.470 -691.171
201606 -317.667 101.688 -421.502
201609 -207.222 101.861 -274.489
201612 -157.111 101.863 -208.108
201703 -380.222 102.862 -498.746
201706 -233.667 103.349 -305.062
201709 -327.923 104.136 -424.884
201712 -176.231 104.011 -228.613
201803 -86.553 105.290 -110.916
201806 -56.444 106.317 -71.633
201809 -42.578 106.507 -53.939
201812 -67.267 105.998 -85.625
201903 -59.044 107.251 -74.280
201906 -49.245 108.070 -61.483
201909 -34.175 108.329 -42.566
201912 -5.466 108.420 -6.802
202003 -7.617 108.902 -9.437
202006 -4.537 108.767 -5.628
202009 -4.115 109.815 -5.056
202012 -3.939 109.897 -4.836
202103 -4.705 111.754 -5.681
202106 -2.448 114.631 -2.881
202109 -2.188 115.734 -2.551
202112 -2.226 117.630 -2.553
202203 -3.481 121.301 -3.872
202206 -2.948 125.017 -3.182
202209 13.237 125.227 14.262
202212 -1.338 125.222 -1.442
202303 -2.861 127.348 -3.031
202306 -3.788 128.729 -3.970
202309 -0.390 129.860 -0.405
202312 -0.447 129.419 -0.466
202403 -0.231 131.776 -0.237
202406 -0.253 132.554 -0.258
202409 -0.558 133.029 -0.566
202412 -0.925 133.157 -0.937
202503 -0.447 134.927 -0.447

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CervoMed  (NAS:CRVO) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


CervoMed Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of CervoMed's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CervoMed Business Description

Industry
Traded in Other Exchanges
Address
20 Park Plaza, Suite 424, Boston, MA, USA, 02116
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Executives
William Robert Elder officer: GC & Secretary 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Sylvie Gregoire director, 10 percent owner 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
John William Tanner officer: Chief Financial Officer C/O EIP PHARMA, INC., 20 PARK PLAZA, SUITE 424, BOSTON MA 02116
Frank Zavrl director C/O PUMA BIOTECHNOLOGY INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Marwan Sabbagh director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Kelly Blackburn officer: VP, Clinical Development C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jeffrey V. Poulton director 300 THIRD STREET, CAMBRIDGE MA 02142
John J Alam director, 10 percent owner, officer: CEO and President 130 WAVERLY STREET, CAMBRIDGE MA 02139
Jill Davidson director 300 EAST MAIN STREET, SUITE 101, CHARLOTTESVILLE VA 22902
Raven Jaeger officer: Chief Regulatory Officer 300 EAST MAIN STREET, SUITE 201, CHARLOTTESVILLE VA 22902
Eric Francois director C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Diana M Lanchoney director 1317 CARLTON AVE, SUITE 200, CHARLOTTESVILLE VA 22902
Cobuzzi Robert Joseph Jr. director C/O DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Christopher D Galloway officer: Chief Medical Officer 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Jane H Hollingsworth director DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902